$Vktx so BL says license talks ongoing with 0214 and 2809 but won’t give commentary

$VKTX definitely analysts getting the move from subq to oral for maintenance and also combinations including VK2735, the latter which start next year

$VKTX Ph3 starts this month AND “Another study that we’re really interested in getting going, and we’ll start it in the third quarter here, is to evaluate the PK when you transition somebody from a weekly dose to a monthly regimen. So this study will rapidly titrate” LIVE

$VKTX agreement with supplier for $10bn of supply

$VKTX LIVE

$VKTX. I seem to recall last year they went from 3000 to 2000 there were 15m shares that had to be sold (there are more funds tracking 3000 than 2000). This would appear to suggestViking have come out of 2000 to move to 3000, which means that stock would have to be repurchased

$VKTX literally hundreds of posts from this guy, since he first appeared spouting “single figures” and “FDA issues”. Viking moved +46% since he started posting negatively. That must hurt and is just stupid; money lost with every post.

$VKTX onlinelibrary.wiley.com/doi/10.1002/ob… Looks like a full report on Venture just published

$VKTX clearly going straight to Ph 3

$VKTX ir.vikingtherapeutics.com/2026-02-04-Vik…

$VKTX For me it’s interesting that this year the wording from Viking has changed from “Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 2 trial” to now saying “Concurrently, the company is evaluating an oral formulation of VK2735 in obesity”

$VKTX Full reversal from HIMs “Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims said” From Apple News

$VKTX. Interesting that this new job went up at the weekend. Senior clinical data manager recruiting.paylocity.com/Recruiting/Job…

$VKTX 12-18 months ahead on oral now. Saving …. 2b design + startup: 3–4 months •Enrolment: 4–6 months •24–36 week treatment period •Data readout + analysis: 3–4 months •FDA meeting to align on Phase 3: 2–3 months That’s roughly: +12 to 18 months

$VKTX on partnership from earnings call. Summary: